Niacin/Laropiprant Tablet for South and Southeast Asians With Low HDL at Risk for Cardiovascular Disease (MK-0524A-108 AM1)

This study has been terminated.

(In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs)

Sponsor:

Information provided by (Responsible Party):

Merck

ClinicalTrials.gov Identifier:

NCT01414166

First received: August 9, 2011

Last updated: March 21, 2013

Last verified: March 2013

History of Changes

Full Text View
Tabular View
No Study Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been terminated.
Study Completion Date:	February 2013
Primary Completion Date:	February 2013 (Final data collection date for primary outcome measure)

To Top